Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care: 2-year outcomes and predictors
Brahe CH et al. Rheumatology (Oxford) 2018: key244. doi: 10.1093/rheumatology/key244
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.